Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
1.030
+0.045 (4.57%)
At close: Apr 17, 2026, 4:00 PM EDT
0.9770
-0.0530 (-5.15%)
After-hours: Apr 17, 2026, 5:16 PM EDT
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $20.00K in the quarter ending February 28, 2026, a decrease of -88.51%. This brings the company's revenue in the last twelve months to $368.00K, down -30.03% year-over-year. In the fiscal year ending August 31, 2025, Lexaria Bioscience had annual revenue of $705.92K with 52.05% growth.
Revenue (ttm)
$368.00K
Revenue Growth
-30.03%
P/S Ratio
65.79
Revenue / Employee
$52,571
Employees
7
Market Cap
25.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 705.92K | 241.65K | 52.05% |
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuphoria Therapeutics | 14.99M |
| Barinthus Biotherapeutics | 14.97M |
| Curis | 9.44M |
| Marker Therapeutics | 3.55M |
| Daré Bioscience | 1.03M |
| Exicure | 500.00K |
| Outlook Therapeutics | 205.70K |
LEXX News
- 2 days ago - Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property - TheNewswire
- 10 days ago - Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval - TheNewswire
- 16 days ago - Lexaria to Begin New Human Clinical Study in GLP-1 - TheNewswire
- 22 days ago - Lexaria's Robust Patent Portfolio Continues to Grow - Accesswire
- 24 days ago - Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - TheNewswire
- 6 weeks ago - Lexaria Announces New R&D Plans for 2026 - Accesswire
- 2 months ago - Lexaria Announces Positive Final Results From Human Pilot Study #5 - Accesswire
- 3 months ago - Lexaria Awarded Six Additional Patents - Accesswire